Communiqués PolyPeptide Group AG London S.E.

Actions

0AAJ

CH1110760852

Produits pharmaceutiques

Marché Fermé - London S.E. 12:25:26 06/08/2026			Varia. 5j.	Varia. 1 janv.
43,98 ^CHF	+0,40%		-0,06%	+69,54%

08/09	Amylyx Pharmaceuticals, Inc. conclut des accords de fabrication et d'approvisionnement avec Bachem Americas, Inc. et Polypeptide Group AG	CI
31/08	L'indice phare suisse dans le rouge face à la persistance des tensions au Moyen-Orient	MT

Communiqués

31/08	PolyPeptide Group: Samsung Peptide AG publishes offer prospectus for public tender offer for PolyPeptide Group AG	EQ
13/08	PolyPeptide delivers +42% growth in H1 2026 and improved EBITDA margin; 2026 full-year guidance updated, now expecting 25-30% revenue growth and high-teens EBITDA margin	EQ
20/07	PolyPeptide : Samsung Biologics announces tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share	PU
20/07	PolyPeptide Group: Samsung Biologics announces tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share	EQ
14/04	PolyPeptide Group AG takes note of market rumors and speculation	EQ
08/04	PolyPeptide announces results of the annual General Meeting 2026	EQ
19/03	PolyPeptide strengthens financing structure through expansion of existing credit facility	EQ
17/03	PolyPeptide publishes invitation to the annual General Meeting 2026	EQ
12/03	PolyPeptide : Media release (PolyPeptide FY 2025 Media release)	PU
12/03	PolyPeptide : Full-year earnings presentation (PolyPeptide Group FY 2025 presentation)	PU
12/03	PolyPeptide : Annual Report	PU
12/03	PolyPeptide delivers strong revenue growth and marked improvement in profitability	EQ
19/01	PolyPeptide successfully closes financial year 2025 with strong revenue growth and marked improvement in profitability	EQ
12/12	PolyPeptide and Lupin Manufacturing Solutions Form Strategic Alliance to Meet Growing Demand for Peptide Supply in Metabolic Therapies	EQ
19/11	PolyPeptide : Jefferies London Healthcare Conference, CEO presentation, November 2025 (20251119 PolyPeptide Jefferies London HC Conference)	PU
28/10/25	Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market	AQ
24/10/25	PolyPeptide : Capacity expansion underway at our Ambernath facility	PU
22/09/25	PolyPeptide Group achieves significant milestone in Malmö expansion project	EQ
01/09/25	Alzinova testimonial: Alzheimer’s peptide vaccine with PolyPeptide	PU
12/08/25	PolyPeptide : Media release (English) (PolyPeptide H1 2025 Media release E FINAL )	PU
12/08/25	PolyPeptide : Half-year earnings presentation (PolyPeptide Group H1 2025 presentation)	PU
12/08/25	PolyPeptide delivers +24% growth in H1 2025, successful ramp-up at its Belgian site, 2025 full-year guidance revised towards the upper end of the range	EQ
23/05/25	PolyPeptide announces expansion of existing credit facilities	EQ
09/04/25	PolyPeptide announces results of the annual General Meeting 2025	EQ
18/03/25	PolyPeptide : publishes invitation to the annual General Meeting 2025	PU